MyFinsight

HomeCompareAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Privacy Policy
  • Contact

Follow Us

  • Thread
  • X.com
  • Instagram

© 2026 MyFinsight. All rights reserved.

Recent SEC Filings
9/24BLACKBERRY Ltd(BB)9/24PAYCHEX INC(PAYX)9/23GENERAL MILLS INC(GIS)9/22ADOBE INC.(ADBE)9/18KROGER CO(KR)9/24BLACKBERRY Ltd(BB)9/24PAYCHEX INC(PAYX)9/23GENERAL MILLS INC(GIS)9/22ADOBE INC.(ADBE)9/18KROGER CO(KR)
||
||

Income Overview

Net Income
-$1,380K
EPS
-$0.03
Unit: Thousand (K) dollars
Income Statement
2026-06-30
2026-03-31
2025-12-31
Research and development expenses
719
679
1,566*
General and administrative expenses
661
1,279
389*
Total operating expenses
1,380
1,958
1,955
Operating loss
-1,380
-1,958
-1,955*
Other expense direct listing offering costs
-
586
291*
Net loss and comprehensive loss
-1,380
-2,544
-2,246
Basic EPS
-0.03
-0.05
-0.049
Diluted EPS
-0.03
-0.05
-0.049
Basic Average Shares
48,278,370
47,219,329
45,422,581
Diluted Average Shares
48,278,370
47,219,329
45,422,581
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

PLYX Income Statement Sankey DiagramSankey diagram visualizing PLYX income statement for the periodNet loss andcomprehensive loss-$1,380K Operating loss-$1,380K Total operatingexpenses$1,380K Research and developmentexpenses$719K General andadministrative expenses$661K

Polaryx Therapeutics, Inc. (PLYX)

Polaryx Therapeutics, Inc. (PLYX)